Biotechnology & Medical Research
LIST1044Related Stocks
News
Bio-Techne Acquired by Merck for $11.3 Billion at a Premium, Jumps Over 20% Premarket.
TradingKey - On June 25, Eastern Time, Germany's Merck Group announced that it will acquire US life sciences company Bio-Techne (TECH) for $73 per share in an all-cash transaction, representing an enterprise value of approximately $11.3 billion.
Nuvalent Surges 39% Premarket. GSK Acquires for $10.6 Billion at 40% Premium, New CEO’s First Big Bet on Lung Cancer Field
TradingKey - British pharmaceutical giant GSK announced on June 9 that it will acquire U.S. biotechnology company Nuvalent (NUVL) for $10.6 billion in an all-cash deal to bolster its lung cancer drug pipeline. This transaction marks GSK's largest acquisition in over a decade and represents the first major strategic move under new CEO Luke Miels.
US Pre-Market: Three Major Index Futures Rise, Nasdaq Leads. Micron Rises Over 4%, Over 10 Billion Acquisition Drives Nuvalent to Surge Nearly 40%
TradingKey - On Tuesday Eastern Time, the three major U.S. stock index futures rose in pre-market trading as AI chip stocks extended their recovery rally. A temporary cooling of tensions in the Middle East led to a pullback in oil prices, boosting market risk appetite. As of press time, Dow futures
P3 Health Partners (PIII) Pullback: Is $12.38 a Re-Entry Buy Opportunity?
TradingKey - P3 Health Partners is at $12.38 after pulling back from $18.52 post-earnings high. Ascending trendline from $5.91 intact. Q1 net income +$3M vs -$44M prior year. EBITDA $26M. Target $14.16.
P3 Health Partners Swung to Profit and Beat EPS by $5.17 — Is PIII Stock a Buy at $10?
TradingKey - P3 Health Partners Q1 2026: EPS +$0.32 vs -$4.85 estimate. Medical margin jumped from $49 to $231 per member. 2026 EBITDA guidance raised to $20–$60M. Lake Street target raised to $14. PIII at $10.
GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?
TradingKey - On April 16, 2026, OpenAI released GPT-Rosalind, a large language model specifically designed for life sciences research. Initial users include pharmaceutical giant Amgen (AMGN), vaccine manufacturer Moderna (MRNA), and the Allen Institute. Following the announcement, the CRO sector saw a broad decline, with IQVIA Holdings (IQV) falling 3.5% and Charles River Laboratories (CRL) dropping 2.6%. Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR) both tumbled over 5% at one point.
